Elon Musk, the founder of Neuralink, has received authorization to initiate human trials involving a groundbreaking brain chip. This development holds the promise of potentially restoring full bodily mobility to individuals suffering from paralysis.
Elon Musk's company, Neuralink, is embarking on a remarkable journey with the launch of human trials.
The first human patient will soon receive a Neuralink device. This ultimately has the potential to restore full body movement.
— Elon Musk (@elonmusk) September 20, 2023
In the long term, Neuralink hopes to play a role in AI risk civilizational risk reduction by improving human to AI (and human to human) bandwidth by… https://t.co/DzqoYI27Ng
Participants in the study will undergo brain surgery as part of the trial.
Our surgical team enhances their skills by training on realistic, patient-specific head and brain models, ensuring surgeries are tailored to each individual for safety and success 🧠 pic.twitter.com/1HvXbeG3Fm
— Neuralink (@neuralink) August 1, 2023
Elon Musk has been dedicated to the goal of connecting the human brain to computers using implants for the past five years.
Prior to this, Neuralink conducted experiments involving animals, although they encountered challenges, including the unfortunate death of a monkey during a video game experiment in 2022.
The trials involved macaque monkeys with implanted chips that communicated with computers via Bluetooth technology.
In April 2021, Neuralink showcased a monkey named Pager playing the computer game Pong solely through thought, without the use of a joystick.
This achievement was made possible by connecting the chip to the monkey's brain and utilizing a computer to anticipate the monkey's intentions.
Elon Musk initially expressed his interest in human testing as early as 2019, but formal requests to the FDA were only made in 2022.
Initially, the FDA expressed concerns about potential movement of implant components within the brain during removal, posing risks.
However, in May 2023, Neuralink received FDA approval to conduct their inaugural study involving human participants.
We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study!
— Neuralink (@neuralink) May 25, 2023
This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our…
Looking ahead, Neuralink aims to significantly enhance human communication with AI and among humans, potentially mitigating the risks associated with artificial intelligence on a societal scale.